Abdul Hai Mansoor, MD
Hematology & Oncology · Portland, ORNPI 1790934149
Payments from drug & device makers
Across 409 payments — averaging $8559.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.1M
- Incyte Corporation$1.1M
- Genentech, Inc.$603K
- Karyopharm Therapeutics Inc.$153K
- Regeneron$149K
- ADC Therapeutics America, Inc.$143K
- plus $310K from 9 others
Across 3 payments — averaging $2397.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$6K
- Takeda Pharmaceuticals U.S.A., Inc.$829
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $1,071,338 |
| Incyte Corporation | 144 | $1,071,249 |
| Genentech, Inc. | 53 | $603,140 |
| Karyopharm Therapeutics Inc. | 34 | $153,207 |
| Regeneron | 45 | $148,795 |
| ADC Therapeutics America, Inc. | 24 | $142,798 |
| AbbVie | 25 | $113,536 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $80,249 |
| TG Therapeutics, Inc. | 22 | $33,047 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28,900 |
| Janssen Research & Development, LLC | 15 | $22,563 |
| Agios Pharmaceuticals, Inc. | 4 | $14,800 |
| Pharmacyclics LLC, An Abbvie Company | 11 | $10,046 |
| Eisai Inc. | 2 | $6,323 |
| F. Hoffmann-la Roche AG | 1 | $750 |
How this compares
$3,500,742 in reported general payments places this provider in the 90th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 193 | $2,418,468 |
| PomalystPomalidomide | 55 | $1,364,792 |
| BrukinsaZanubrutinib | 59 | $777,065 |
| JakafiRuxolitinib Phosphate | 74 | $628,017 |
| TasignaNilotinib Hcl | 23 | $447,567 |
| CalquenceAcalabrutinib Maleate | 23 | $330,764 |
| PromactaEltrombopag Olamine | 13 | $135,178 |
| AlvaizEltrombopag Choline | 25 | $127,969 |
| VenclextaVenetoclax | 25 | $93,597 |
| XareltoRivaroxaban | 40 | $26,740 |
| NivestymFilgrastim-Aafi | 36 | $24,138 |
| EliquisApixaban | 21 | $13,124 |
| GranixTbo-Filgrastim | 16 | $9,385 |
| Posaconazole | 32 | $6,095 |
| Acyclovir | 182 | $4,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $28,900 | $1,364,79255 claims |
| Incyte CorporationJakafi | $1,071,249 | $628,01774 claims |
| NovartisTasigna, Promacta | $1,071,338 | $582,74536 claims |
| AbbVieVenclexta | $113,536 | $93,59725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 hematology & oncology providers in Oregon.
Other hematology & oncology in Portland
- Michael HeinrichPortland$25M
- Jay AndersenPortland$8.3M
- Elie TraerPortland$6.5M
- Jacqueline VukyPortland$5.4M
- Sandeep MashruPortland$4.6M
- Aimee KohnPortland$3.3M
- Tibor KovacsovicsPortland$2.7M
- Emerson ChenPortland$2.5M
- Brian DrukerPortland$2.5M
- Tony HoPortland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.